'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Clicks: 344
ID: 55200
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Abstract is not available for this article.
Login to Search Abstract
Reference Key
mastellos2019stealthnature Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mastellos, Dimitrios C;Blom, Anna M;Connolly, E Sander;Daha, Mohamed R;Geisbrecht, Brian V;Ghebrehiwet, Berhane;Gros, Piet;Hajishengallis, George;Holers, V Michael;Huber-Lang, Markus;Kinoshita, Taroh;Mollnes, Tom E;Montgomery, Robert A;Morgan, B Paul;Nilsson, Bo;Pio, Ruben;Ricklin, Daniel;Risitano, Antonio M;Taylor, Ronald P;Mantovani, Alberto;Ioannidis, John P A;Lambris, John D;
Journal Nature Immunology
Year 2019
DOI
10.1038/s41590-019-0503-1
URL
Keywords
Docking Cancer Cytotoxicity doxorubicin admet cdk7

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.